Mesh : Adenocarcinoma / drug therapy genetics pathology Afatinib Anaplastic Lymphoma Kinase Antineoplastic Combined Chemotherapy Protocols / therapeutic use Bevacizumab / administration & dosage Carcinoma, Large Cell / drug therapy genetics pathology Carcinoma, Non-Small-Cell Lung / drug therapy genetics pathology Crizotinib Docetaxel Erlotinib Hydrochloride / administration & dosage Gefitinib Genes, erbB-1 / genetics Humans Lung Neoplasms / drug therapy genetics pathology Maintenance Chemotherapy Pemetrexed / administration & dosage Pyrazoles / administration & dosage Pyridines / administration & dosage Quinazolines / administration & dosage Receptor Protein-Tyrosine Kinases / genetics Singapore Taxoids / administration & dosage Translocation, Genetic

来  源:   DOI:

Abstract:
BACKGROUND: The SCAN lung cancer workgroup aimed to develop Singapore Cancer Network (SCAN) clinical practice guidelines for the use of systemic therapy in advanced non-small cell lung cancer (NSCLC) in Singapore.
METHODS: The workgroup utilised a modified ADAPTE process to calibrate high quality international evidence-based clinical practice guidelines to our local setting.
RESULTS: Five international guidelines were evaluated- those developed by the National Comprehensive Cancer Network (2014), the European Society of Medical Oncology (2014), the National Institute of Clinical Excellence (2012), the Scottish Intercollegiate Guidelines Network (2014) and Cancer Care Council Australia (2012). Recommendations on systemic treatment for advanced NSCLC were produced.
CONCLUSIONS: These adapted guidelines form the SCAN guidelines 2015 for systemic therapy of advanced or metastatic NSCLC.
摘要:
暂无翻译
公众号